Laxative Effect of Spicatoside A by Cholinergic Regulation of Enteric Nerve in Loperamide-Induced Constipation: ICR Mice Model.
Animals
Aquaporins
/ metabolism
Body Weight
Cholinergic Agents
/ pharmacology
Constipation
/ chemically induced
Disease Models, Animal
Eating
Enteric Nervous System
/ drug effects
Gastrointestinal Hormones
/ metabolism
Gene Expression Regulation
Laxatives
/ pharmacology
Liliaceae
/ chemistry
Loperamide
Mice
Mice, Inbred ICR
Mucins
/ metabolism
Plant Extracts
/ chemistry
Plant Roots
/ chemistry
Protein-Tyrosine Kinases
/ metabolism
Saponins
/ isolation & purification
Signal Transduction
C-kit
aquaporin
constipation
gastrin
mucin
muscarinic acetylcholine receptors
spicatoside A
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
04 Mar 2019
04 Mar 2019
Historique:
received:
24
01
2019
revised:
26
02
2019
accepted:
28
02
2019
entrez:
7
3
2019
pubmed:
7
3
2019
medline:
8
10
2019
Statut:
epublish
Résumé
Researches on spicatoside A (SpiA)-containing natural products suggest the possibility of SpiA as a potential laxative to alleviate chronic constipation. However, no studies have been conducted with single compound administration of SpiA. To verify the laxative effects and mechanism of action of SpiA on chronic constipation, we investigated alterations in the excretion parameters, histological structure, and cholinergic regulation of the enteric nerve in the colons of Institute of Cancer Research (ICR) mice with loperamide (Lop)-induced constipation after exposure to 20 mg/kg of SpiA. Decrease in the number, weight and water contents of stools in the Lop+Vehicle treated group significantly recovered after SpiA treatment, and alterations in the histological structure and transmission electron microscopy (TEM) images were improved in the Lop+SpiA treated group. Similar recovery effects were observed in the ability for mucin secretion and expression of the membrane water channel gene (aquaporin 8, AQP8). Furthermore, significant improvements were observed in the acetylcholinesterase (AChE) activity and acetylcholine receptors' (AChRs) downstream signaling pathway after treatment of SpiA. The levels of gastrointestinal (GI) hormones including cholecystokinin (CCK) and gastrin were also remarkably enhanced in the Lop+SpiA treated group as compared to the Lop+Vehicle treated group. The expression of receptor tyrosine kinase (C-kit) and protein gene product 9.5 (PGP9.5) in Cajal and neural cells, as well as the phosphorylation of myosin light chain (MLC) in smooth muscle cells, were recovered after SpiA exposure. Taken together, the results of the present study provide the first strong evidence that SpiA improves chronic constipation through muscarinic cholinergic regulation of the enteric nerve in a Lop-induced constipation ICR mice model.
Identifiants
pubmed: 30836659
pii: molecules24050896
doi: 10.3390/molecules24050896
pmc: PMC6429089
pii:
doi:
Substances chimiques
5-(1-(glucopyranosyloxymethyl)ethenyl)-2-methyl-2-cyclohexen-1-one
0
Aquaporins
0
Cholinergic Agents
0
Gastrointestinal Hormones
0
Laxatives
0
Mucins
0
Plant Extracts
0
Saponins
0
Loperamide
6X9OC3H4II
Protein-Tyrosine Kinases
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Research Foundation of Korea
ID : 2017R1D1A3B03032631
Organisme : National Research Foundation of Korea
ID : 2018R1A6A3A01011498
Références
Curr Opin Neurobiol. 2000 Oct;10(5):642-8
pubmed: 11084327
Ann Med. 2006;38(2):116-25
pubmed: 16581697
PLoS One. 2008 Oct 03;3(10):e3348
pubmed: 18833323
Fortschr Chem Org Naturst. 2008;89:45-141
pubmed: 18958994
Chest. 2009 Feb;135(2):505-512
pubmed: 19201713
Eur J Pharmacol. 2009 Oct 12;620(1-3):9-15
pubmed: 19695245
J Ethnopharmacol. 2010 Feb 3;127(2):215-20
pubmed: 19951738
BMC Gastroenterol. 2010 Aug 19;10:95
pubmed: 20723249
Curr Gastroenterol Rep. 2010 Oct;12(5):358-65
pubmed: 20725870
Int J Mol Med. 2011 Mar;27(3):319-27
pubmed: 21165549
Pharmacogn Mag. 2011 Oct;7(28):325-33
pubmed: 22262936
BMC Complement Altern Med. 2012 Mar 10;12:16
pubmed: 22405321
Nat Rev Drug Discov. 2012 Oct;11(10):751-61
pubmed: 22935759
Phytother Res. 2013 Jul;27(7):1054-60
pubmed: 22972571
J Asian Nat Prod Res. 2013 Sep;15(9):1038-49
pubmed: 23944983
Phytomedicine. 2014 Jan 15;21(2):172-6
pubmed: 24060215
BMC Complement Altern Med. 2013 Nov 26;13:333
pubmed: 24274470
J Recept Signal Transduct Res. 2016;36(1):14-20
pubmed: 25299754
Int J Mol Sci. 2014 Nov 28;15(12):21875-95
pubmed: 25464378
Biomed Res Int. 2015;2015:814068
pubmed: 26075266
Molecules. 2015 Nov 27;20(12):21138-56
pubmed: 26633317
PLoS One. 2016 Sep 12;11(9):e0161144
pubmed: 27618438
Lab Anim Res. 2016 Dec;32(4):231-240
pubmed: 28053617
Int J Mol Med. 2018 Feb;41(2):649-658
pubmed: 29207043
Evid Based Complement Alternat Med. 2017;2017:6236904
pubmed: 29445412
Pharm Biol. 2018 Dec;56(1):309-317
pubmed: 29952685
J Clin Med. 2018 Oct 22;7(10):null
pubmed: 30360392
Int J Mol Med. 2019 Jan;43(1):185-198
pubmed: 30387811